Cyclosporine A metabolism by cytochrome P-450III occurs in microsomes from rat liver but not from normal epidermis or psoriatic lesions.

Cyclosporine A is efficacious in the treatment of psoriasis when taken orally or injected intralesionally but not topically. Lack of penetration to necessary locations or rapid metabolism during passage through the epidermis may account for the ineffectiveness. Cytochromes P-450III in the liver are known to be involved in cyclosporine metabolism and inactivation. This study was undertaken to determine if an epidermal cytochrome P-450III exists that can inactivate topical cyclosporine A. Rats were treated with the macrolide antibiotic erythromycin to induce the cytochrome P-450III family of enzymes. Microsomal fractions were prepared from liver and epidermis of rats and from lesional areas of psoriasis patients. NADPH cytochrome C reductase activity was determined as a positive control for microsomal enzymatic activity. Formation of metabolite 1, the predominant metabolite of cyclosporine A, by liver microsomes was increased 193% after 10 d erythromycin treatment. The cytochrome P-450 dependent activity in microsomes from the epidermis of control and erythromycin-treated rats and in microsomes from psoriatic tissue was at the detection limits of the assay system. Cytochrome P-450III gene family mRNA were detectable by polymerase chain reaction in liver but not in psoriatic or normal epidermis. The lack of detectable P-450III mRNA and the absence or minimal conversion of cyclosporine A to inactive metabolites by epidermal microsomes suggest that the ineffectiveness of topical cyclosporine A in psoriasis may not be due to inactivation of cyclosporine A by cytochrome P-450 in the skin.

[1]  I. Coulson,et al.  (5) Topical cyclosporin A in alopecia totalis: failure of therapeutic effect due to lack of penetration , 1989 .

[2]  P. Chambon,et al.  A third human retinoic acid receptor, hRAR-gamma. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[3]  T. Aoyama,et al.  Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. , 1989, The Journal of biological chemistry.

[4]  J. Derancourt,et al.  Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[5]  D. Rappolee,et al.  Novel method for studying mRNA phenotypes in single or small numbers of cells , 1989, Journal of cellular biochemistry.

[6]  T. Annesley,et al.  Levels of cyclosporin in epidermis of treated psoriasis patients differentially inhibit growth of keratinocytes cultured in serum free versus serum containing media. , 1988, The Journal of investigative dermatology.

[7]  T. Kronbach,et al.  Cyclosporine metabolism in human liver: Identification of a cytochrome P‐450III gene family as the major cyclosporine‐metabolizing enzyme explains interactions of cyclosporine with other drugs , 1988, Clinical pharmacology and therapeutics.

[8]  H. Valdimarsson,et al.  INTRALESIONAL INJECTION OF CYCLOSPORIN IN PSORIASIS , 1988, The Lancet.

[9]  O. Mcbride,et al.  Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. , 1988, DNA.

[10]  A. Gilhar,et al.  Topical cyclosporins in psoriasis , 1988 .

[11]  K. Mullis,et al.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. , 1988, Science.

[12]  C. Griffiths,et al.  TOPICAL CYCLOSPORIN AND PSORIASIS , 1987, The Lancet.

[13]  G. Bernier,et al.  Cyclosporine for treatment of psoriasis. , 1987, The New England journal of medicine.

[14]  J. Billings,et al.  Cyclosporine improves psoriasis in a double-blind study. , 1986, JAMA.

[15]  P. Beaune,et al.  Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[16]  C. Griffiths,et al.  Clearance of psoriasis with low dose cyclosporin. , 1986, British medical journal.

[17]  P. Watkins,et al.  Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[18]  T. Annesley,et al.  Liquid-chromatographic analysis for cyclosporine with use of a microbore column and small sample volume. , 1986, Clinical chemistry.

[19]  P. Watkins,et al.  Identification of an inducible form of cytochrome P-450 in human liver. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[20]  G. Maurer.  Metabolism of cyclosporine. , 1985, Transplantation proceedings.

[21]  H. Mukhtar,et al.  Aryl hydrocarbon hydroxylase, epoxide hydrolase, and benzo[a]-pyrene metabolism in human epidermis: comparative studies in normal subjects and patients with psoriasis. , 1984, The Journal of investigative dermatology.

[22]  S. Boyce,et al.  Calcium-regulated differentiation of normal human epidermal keratinocytes in chemically defined clonal culture and serum-free serial culture. , 1983, The Journal of investigative dermatology.

[23]  J. Cream,et al.  (19) Arsenical keratoses‐response to etretinate and electron beam therapy , 1983 .

[24]  J. Fraki,et al.  Correlation of epidermal plasminogen activator activity with disease activity in psoriasis , 1983, The British journal of dermatology.

[25]  W. Rutter,et al.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.

[26]  W. Mueller,et al.  Cyclosporin A for psoriasis. , 1979, The New England journal of medicine.

[27]  P. Harper,et al.  PRENATAL PREDICTION OF MYOTONIC DYSTROPHY , 1976, The Lancet.

[28]  P. Noone,et al.  AMIKACIN RESISTANCE DEVELOPING IN PATIENT WITH PSEUDOMONAS ÆRUGINOSA BRONCHOPNEUMONIA , 1976, The Lancet.

[29]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[30]  James T. Elder,et al.  Protooncogene expression in normal and psoriatic skin. , 1990, The Journal of investigative dermatology.

[31]  T. Hamilton,et al.  Intralesional cyclosporine in the treatment of psoriasis. A clinical, immunologic, and pharmacokinetic study. , 1990, Journal of the American Academy of Dermatology.

[32]  H. Loosli,et al.  Disposition of cyclosporine in several animal species and man. I. Structural elucidation of its metabolites. , 1984, Drug metabolism and disposition: the biological fate of chemicals.

[33]  H. Mukhtar,et al.  Epidermis: a site of drug metabolism in neonatal rat skin. Studies on cytochrome P-450 content and mixed-function oxidase and epoxide hydrolase activity. , 1982, Molecular pharmacology.